[ad_1]
British media outlet The Sky News has called the Oxford University vaccine a “global vaccine” in collaboration with the pharmaceutical giant AstraZeneca because it is cheaper, easier to transport and safer than Modern and Pfizer in the United States. . But British health officials have given the Oxford vaccine the green light, but experts have questions. Even British health officials disagree with the inventors on the efficacy and dosage of the vaccine. The issue was raised in a report by the British news agency Reuters.
AstraZeneca states that taking a full dose after half a dose of the vaccine will provide more protection against infection. British officials disagreed with this statement. This disagreement by UK drug regulators on vaccine dose control is their own assessment. So far, the results of the evaluation have not yet been published.
The Oxford-AstraZeneca vaccine is cheaper and easier to transport than rival vaccines. Uncertainty about determining its most effective dose has been mounting since its efficacy report was published last month.
The AstraZeneca report states that the efficacy of the vaccine is 90 percent if a full dose is taken after half the dose. On the other hand, in the case of two full doses, its effectiveness is 72 percent.
The Oxford researchers claim that the high-efficiency dose was a strange result. That is why more tests will be needed. An investigation by the Reuters news agency later found that the results for the half and full dose may be due to a miscalculation by the Oxford researchers.
Munir Pir Mohammad, head of the British consulting group on the Covid-19 vaccine, justified the suspicion on Wednesday by saying a 90 percent success rate had not been found in the analysis.
At a press conference, he said the higher efficacy rate could be due to the longer interval between the first and second doses of the vaccine. Our idea is that there is an interval interval greater than the dose with the 90 percent efficacy reporting.
Wei Shane Lim, UK director of the Covid-19 vaccine, said the Oxford-Astragene vaccine was 80 percent effective up to 21 days before the second dose.
In this regard, Pirmohammad said that if the interval between two doses is increased from one month to three months, the effectiveness rate of the AstraZeneca-Oxford vaccine could reach 70 percent.
An AstraZeneca spokesperson said after British officials released new details about the vaccine’s effectiveness: “It is the responsibility of regulators to determine how the vaccine should be used.
The UK is trying to deliver the first dose of the vaccine to as many people as possible against a new infectious virus. The country wants to increase the number of people receiving the first dose rather than applying the second dose. Delays in the administration of the second dose are expected to ease pressure on supplies.
The UK Medicines and Health Products Regulatory Authority (MHRA) recommends that there be an interval of four to 12 weeks between the two doses of the AstraZeneca-Oxford vaccine. For Pfizer-Bioentech vaccines, a 21-day break is recommended, but the second dose is recommended within 12 weeks.
Hundreds of British citizens have already taken the first dose since Pfizer was the first country in the world to approve the vaccine. The second dose will start from this week. Pfizer issued a change warning during the second dose. They claim that no testing has been done at different dosing times.
AstraZeneca CEO Pascal Soriot told Britain’s Sunday Times newspaper that while rival vaccines Pfizer and Modern are 95 percent effective, his organization has a winning formula. However, he said he could not say more because no new information had been released yet.
[ad_2]
